US-based Ritedose Pharmaceuticals, a subsidiary of CDMO Ritedose Corporation, has announced the launch of generic unit dose budesonide inhalation suspension (0.5 mg/2 ml) packaged for use in hospitals. Also, at the end of December, the FDA approved the company’s ANDA for two strengths of albuterol inhalation solution, generic equivalents of Mylan’s Accuneb.
Ritedose said that the budesonide suspension is one of five new inhalation products that the company intends to launch in the first quarter of 2022. In addition to other versions of albuterol sulfate, Ritedose already markets levalbuterol, ipatropium bromide, ipatropium/albuterol, and sodium chloride inhalation solutions. Other products listed as “coming soon” in the company’s catalog include additional sodium chloride inhalation solution products and tobramycin inhalation solution.
Ritedose President and CEO Jody Chastain commented, “We’re pleased to add products that complement our already robust inhalation portfolio. With our manufacturing capabilities and annual capacity, we offer our hospital clients an ample, reliable supply of the many products they regularly need.”
Read the Ritedose press release.
